Trade Champions Oncology, Inc. - CSBR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.89 |
| Open | 7.82 |
| 1-Year Change | 55.78% |
| Day's Range | 7.17 - 8.19 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 28, 2025 | 7.30 | -0.51 | -6.53% | 7.81 | 8.20 | 7.17 |
| Apr 25, 2025 | 7.89 | 0.26 | 3.41% | 7.63 | 8.19 | 7.63 |
| Apr 24, 2025 | 7.60 | 0.06 | 0.80% | 7.54 | 7.96 | 7.54 |
| Apr 23, 2025 | 7.86 | 0.01 | 0.13% | 7.85 | 8.06 | 7.74 |
| Apr 22, 2025 | 7.74 | -0.12 | -1.53% | 7.86 | 8.04 | 7.60 |
| Apr 21, 2025 | 7.75 | 0.15 | 1.97% | 7.60 | 8.25 | 7.60 |
| Apr 17, 2025 | 7.85 | -0.09 | -1.13% | 7.94 | 8.41 | 7.65 |
| Apr 16, 2025 | 8.19 | -0.04 | -0.49% | 8.23 | 8.32 | 7.65 |
| Apr 15, 2025 | 8.03 | 0.21 | 2.69% | 7.82 | 8.24 | 7.81 |
| Apr 14, 2025 | 7.88 | 0.54 | 7.36% | 7.34 | 7.88 | 7.30 |
| Apr 11, 2025 | 7.34 | -0.55 | -6.97% | 7.89 | 8.03 | 7.20 |
| Apr 10, 2025 | 7.79 | -0.08 | -1.02% | 7.87 | 8.29 | 7.62 |
| Apr 9, 2025 | 8.45 | 0.79 | 10.31% | 7.66 | 8.81 | 7.54 |
| Apr 8, 2025 | 7.78 | 0.09 | 1.17% | 7.69 | 8.60 | 7.64 |
| Apr 7, 2025 | 7.89 | 0.89 | 12.71% | 7.00 | 8.11 | 6.99 |
| Apr 4, 2025 | 7.48 | -0.01 | -0.13% | 7.49 | 7.97 | 7.39 |
| Apr 3, 2025 | 8.16 | 0.17 | 2.13% | 7.99 | 8.65 | 7.84 |
| Apr 2, 2025 | 8.68 | 0.38 | 4.58% | 8.30 | 8.86 | 8.18 |
| Apr 1, 2025 | 8.43 | -0.11 | -1.29% | 8.54 | 9.05 | 8.23 |
| Mar 31, 2025 | 8.67 | 0.08 | 0.93% | 8.59 | 9.12 | 8.59 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Champions Oncology, Inc. Company profile
About Champions Oncology Inc
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Champions Oncology Inc revenues increased 19% to $36.2M. Net income decreased 14% to $892K. Revenues reflect Pharmacology services segment increase of 66% to $34.5M, Other segment increase from $101K to $1.7M. Net income was offset by research and development increase of 32% to $6.8M (expense), general and administratiojn increase of 32% to $5.9M (expense).
Equity composition
Common Stock $.001 Par, 01/11, 50M auth., 36,853,000 issd. less 1,236,000 shs. in Treas. @ $292K. Insiders & strategic holders own 64.79%. Public Offering 9/85, 40M Units (1 sh. com. + 3 warrants) @ $.01 by the Company. 02/07, Name changedfrom Champions Sports Inc.08/15, 1-for-12 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 619
855 N. Wolfe Street
BALTIMORE
MARYLAND 21205
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com